机构:[1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui-JinHospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai JiaoTong University, Shanghai 200025, P. R. China[2]Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai 200032,P. R. China[3]University of Chinese Academy of Sciences, Beijing 100049, P. R. China[4]Department of Hematologic Oncology, State key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, SunYat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China[5]Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China[6]Medical Center on Aging of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China[7]Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610044, P. R. China四川大学华西医院[8]Biomedical Big Data Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P. R. China浙江大学医学院附属第一医院[9]Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310000, P. R. China
National Natural Science Foundation of
China, Grant/Award Numbers: 81970132,
81770142, 81800144, 31800642; Shanghai Science and Technology Committee,
Grant/Award Number: 20JC1410600;
Shanghai Guangci Translational Medical Research Development Foundation; Shanghai Municipal Education
Commission—Gaofeng Clinical Medicine
Grant Support, Grant/Award Number:
20152504; The Program for Professor of
Special Appointment (Eastern Scholar)
at Shanghai Institute of Higher Learning;
SamuelWaxman Cancer Research Foundation
第一作者机构:[1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui-JinHospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai JiaoTong University, Shanghai 200025, P. R. China
共同第一作者:
通讯作者:
通讯机构:[1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui-JinHospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai JiaoTong University, Shanghai 200025, P. R. China[5]Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China[6]Medical Center on Aging of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China[8]Biomedical Big Data Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P. R. China[9]Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310000, P. R. China[*1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui-Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai JiaoTong University, Shanghai 200025, P. R. China.[*2]Biomedical Big Data Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, P. R. China.[*3]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Rui-Jin Hospital, School of Medicine and School of Life Sciences and Biotechnology, Shanghai JiaoTong University, Shanghai 200025, P. R. China[*4]Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China
推荐引用方式(GB/T 7714):
Hao Zhang,Nuo Cheng,Zhihui Li,et al.DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia.[J].CANCER COMMUNICATIONS.2021,41(11):1116-1136.doi:10.1002/cac2.12234.
APA:
Hao Zhang,Nuo Cheng,Zhihui Li,Ling Bai,Chengli Fang...&Guoyu Meng.(2021).DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia..CANCER COMMUNICATIONS,41,(11)
MLA:
Hao Zhang,et al."DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia.".CANCER COMMUNICATIONS 41..11(2021):1116-1136